APL-1202 + epirubicin

APL-1202 + epirubicin is a combination therapy under investigation primarily for the treatment of non-muscle invasive bladder cancer (NMIBC), particularly in patients who have relapsed after chemotherapy. APL-1202 is a first-in-class, orally available, reversible inhibitor of methionine aminopeptidase II (MetAP2), an enzyme involved in cancer angiogenesis and proliferation. It was originally developed as a repurposed urinary antibiotic (nitroxoline) and has shown potential to enhance the tumor-suppressing effects of chemotherapies and immunotherapies[3][4][6]. Epirubicin is an anthracycline topoisomerase II inhibitor used as a chemotherapeutic agent that works by slowing or stopping the growth of cancer cells[1][5]. The combination aims to improve event-free survival rates compared to chemotherapy alone in NMIBC patients. The developer for APL-1202 is Asieris Pharmaceuticals, which licensed global rights from Johns Hopkins University[3][4].

Other names

nitroxoline + epirubicin